Genprex Inc (GNPX) Stock Price, Quote & News

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 774 4679

Website: www.genprex.com

Address:

3300 Bee Cave Road, Suite 650-227, Austin, United States

TwongStocks Apr. 29 at 8:55 PM

$GNPX Definitive proxy filed for June 18 Annual Meeting. https://www.sec.gov/ix?doc=/Archives/edgar/data/1595248/000143774926013906/gnpx20260417_def14a.htm No major changes from the preliminary proxy filed on Apr 17. Prop 5 to approve a reverse split is still on the ballot. Record date is April 24. As of Apr 24, there were 10,417,400 shares outstanding and entitled to vote. In the preliminary proxy, they reported 9,205,437 shares outstanding as of Apr 15. A net increase of 1,211,963 shares between Apr 15 and Apr 24.

0 · Reply

zannnn Apr. 29 at 8:28 PM

$GNPX

0 · Reply

TwongStocks Apr. 29 at 6:04 PM

$GNPX Latest disclosure filing from Congressman Moore, filed Apr 28. Sold four stocks in April. No reported sales of GNPX. https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2026/20034424.pdf

0 · Reply

Dave790 Apr. 29 at 3:13 PM

$GNPX shitty company, I hope our money isn't enough to pay for your healthcare, shit!

0 · Reply

DKingDK90 Apr. 29 at 1:56 PM

$GNPX Market goes down, this goes down. Market goes up, this stays down. I have some hope on this ticker, but it's starting to get on my nerves...

1 · Reply

daybaron Apr. 29 at 1:46 PM

$GNPX no next stop the $.60's

0 · Reply

daybaron Apr. 29 at 1:43 PM

$GNPX mother of god, what a fucking abortion. not sure i would shed a tear if luigi mangione visited the facility

0 · Reply

P_etheris Apr. 29 at 1:30 PM

$GNPX Mr Hillbilly and some other bots pumping😂😂😂 Cause they are probably deep in red… as they pump for months and months without reasonable DD 🤷🏻‍♂️ Watch that drop today ☝️ It took a while, must say, expected it 2 days ago, but it looks like today or latest tomorrow we will touch 80c🚨

0 · Reply

zannnn Apr. 29 at 11:09 AM

$GNPX

0 · Reply

byers07 Apr. 29 at 10:56 AM

$GNPX

0 · Reply

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Apr 22, 2026, 7:00 AM EDT - 7 days ago

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

Apr 21, 2026, 7:00 AM EDT - 8 days ago

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

Apr 20, 2026, 7:00 AM EDT - 9 days ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Mar 18, 2026, 7:00 AM EDT - 6 weeks ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Mar 10, 2026, 7:00 AM EDT - 7 weeks ago

Genprex to Participate at BIO Europe Spring 2026

Feb 23, 2026, 8:00 AM EST - 2 months ago

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Feb 10, 2026, 8:00 AM EST - 2 months ago

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Jan 7, 2026, 7:00 AM EST - 4 months ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Jan 6, 2026, 7:00 AM EST - 4 months ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Nov 24, 2025, 7:00 AM EST - 5 months ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 19, 2025, 7:00 AM EST - 5 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 18, 2025, 7:00 AM EST - 5 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 4, 2025, 7:00 AM EST - 6 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Oct 28, 2025, 11:19 AM EDT - 6 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 7:00 AM EDT - 6 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 8:12 AM EDT - 6 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 7:00 AM EDT - 6 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 2, 2025, 8:30 AM EDT - 8 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Aug 18, 2025, 9:29 AM EDT - 9 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 4, 2025, 8:30 AM EDT - 9 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Jun 24, 2025, 9:25 AM EDT - 11 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 11 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 3, 2025, 7:00 AM EDT - 11 months ago

Genprex to Participate at BIO 2025 International Convention

May 29, 2025, 7:00 AM EDT - 11 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 28, 2025, 7:00 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 7, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 6, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 22, 2025, 8:15 AM EDT - 1 year ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 25, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 4, 2025, 8:15 AM EST - 1 year ago

Genprex to Participate at BIO Europe Spring 2025

Feb 19, 2025, 8:15 AM EST - 1 year ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025, 8:15 AM EST - 1 year ago

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

TwongStocks Apr. 29 at 8:55 PM

0 · Reply

zannnn Apr. 29 at 8:28 PM

$GNPX

0 · Reply

TwongStocks Apr. 29 at 6:04 PM

$GNPX Latest disclosure filing from Congressman Moore, filed Apr 28. Sold four stocks in April. No reported sales of GNPX. https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2026/20034424.pdf

0 · Reply

Dave790 Apr. 29 at 3:13 PM

$GNPX shitty company, I hope our money isn't enough to pay for your healthcare, shit!

0 · Reply

DKingDK90 Apr. 29 at 1:56 PM

$GNPX Market goes down, this goes down. Market goes up, this stays down. I have some hope on this ticker, but it's starting to get on my nerves...

1 · Reply

daybaron Apr. 29 at 1:46 PM

$GNPX no next stop the $.60's

0 · Reply

daybaron Apr. 29 at 1:43 PM

$GNPX mother of god, what a fucking abortion. not sure i would shed a tear if luigi mangione visited the facility

0 · Reply

P_etheris Apr. 29 at 1:30 PM

0 · Reply

zannnn Apr. 29 at 11:09 AM

$GNPX

0 · Reply

byers07 Apr. 29 at 10:56 AM

$GNPX

0 · Reply

William_H_Bonney Apr. 29 at 9:45 AM

$GNPX $COSM $GNS 99,99% of the people always blame the certain stock and company if it declines. Yes, I’m aware about the dilution here in GNPX etc, but does NO ONE see what’s going on in the market in general(small caps) The same shorting algos are controlling stock after stock… How many stocks haven’t lost 90+% last 6-12 months ? For how long will people continue to add money into this shorting scheme? I stopped a LONG time ago… Just curious to hear how sober other Stocktwits users are

0 · Reply

OverTheCounter Apr. 28 at 9:27 PM

$GNPX Look like this is over. Glad I got out with a small loss

1 · Reply

uptrend2025 Apr. 28 at 8:48 PM

$GNPX I not add until this settles. With their ATM usage I will feel safe to add around $0.55. They have a $58 million ATM, which is crazy.

0 · Reply

StockCaptain7 Apr. 28 at 3:30 PM

$GNPX https://www.webullapp.co.uk/news-detail/14789324387935232?theme=1&hl=en&color=2&_v=1&tickerId=950052394&disSymbol=GNPX&sourcePage=Stock_NewsList&sp=0&hl=en

0 · Reply

zannnn Apr. 28 at 11:38 AM

$GNPX

0 · Reply

P_etheris Apr. 28 at 11:36 AM

$GNPX Small pump…straight down…(just for new short positions) Still expecting 80-85c today🤦🏻‍♂️ Insane 🤔 This is how WS and big pharma destroy small biotechs with great potential 😡

1 · Reply

P_etheris Apr. 28 at 11:28 AM

$GNPX Tim Moore after 3x averaging down this 💩 and seeing Shareholders meeting seeking 50:1 R/S approval looking at the CEO photo🤣

1 · Reply

TwongStocks Apr. 28 at 11:17 AM

$GNPX The abstract for this is available for download here https://download.asgct.org/2026ASGCTAbstractPublication.pdf 2419 Pancreatic Delivery of AAV-Pdx1/MafA Reverses Hyperglycemia in a Preclinical Model of Type 2 Diabetes More preclinical data from the Diabetes program.

0 · Reply

SPARTANVI Apr. 28 at 11:09 AM

$TIVC Potential to pull a nice move Bottom play low floater Ticker change to $VBIO Crazy potential here ⏰️🔥 $MLEC $SKLZ $GNPX

0 · Reply

TwongStocks Apr. 28 at 11:03 AM

$GNPX Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-diabetes-gene-therapy-for-type-2-diabetes-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting-302755179.html

0 · Reply

ka1954 Apr. 28 at 11:02 AM

$GNPX why more news? why? shorts use every news to short even more

0 · Reply

ka1954 Apr. 28 at 10:43 AM

$GNPX at market highest, this is at all time low. let me guess, market corrects and this will also get clobbered more

0 · Reply

Market Cap	9.23M
Revenue (ttm)	0.00
Net Income (ttm)	-16.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	403,100
Avg Vol	1,032,488
Day's Range	N/A - N/A
Shares Out	9.05M
Stochastic %K	6%
Beta	-0.69
Analysts	Strong Buy
Price Target	$7.50